Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 2Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1

Interventions

Specimen Handling 641pembrolizumab 585Magnetic Resonance Spectroscopy 555Carboplatin 431Cyclophosphamide 381Cisplatin 379Biopsy 376Nivolumab 315Paclitaxel 314Gemcitabine 308Radiotherapy 286Bevacizumab 235Dexamethasone 218fludarabine 206Docetaxel 194durvalumab 189Oxaliplatin 189venetoclax 187Rituximab 175Fluorouracil 175atezolizumab 172Pemetrexed 167Capecitabine 164Radiosurgery 162Doxorubicin 162Radiation 160Ipilimumab 146Lenalidomide 140Leucovorin 138Etoposide 134

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Omacor × 90 days × Clear all
NCT06195306 2026-05-20

Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction

National Cancer Institute (NCI)

Phase 2 Recruiting
66 enrolled
Breast

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT04268134 2026-05-06

ALTA

University of Michigan Rogel Cancer Center

Phase 2 Completed
77 enrolled 13 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡